Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analy

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Ba

Commercial launch supported by a dedicated national sales force, payer and institutional access, and

Scienture launches Rezenopy, a 10 mg naloxone nasal spray for opioid overdoses, fulfilling initial U

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

WD-40 Co (WDFC) shares rise sharply in pre-market trading after reporting better-than-expected thir

Scienture Holdings shares jumped 23.54% overnight after the company completed manufacturing inventor

The Company expects REZENOPY™ to become commercially available for purchase in August. The Company i

Commercial availability expected in August as the Company advances the rollout of the highest-dose F

The Company recently secured additional payor coverage representing approximately 12.5 million incre

Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescr

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements,

Scienture expands Rezenopy access through a major health plan ahead of launch, adding coverage for m

5,000+ Healthcare Facilities Reached ThroughGPO Agreements, Covering ~60% of Institutional GPO Marke

COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding com

U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June

COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"),

Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.08) per share which beat the analy

Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension fo

Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension

U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a s

U. S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a

https://sam.gov/opp/cd98e3d515624c65afe83187b80993a7/view

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and plan

COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"

Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (G

Scienture reports 216% revenue growth in 2025, driven by Arbli uptake, patent wins, and expanded hea

Scienture (NASDAQ: SCNX - Get Free Report) is anticipated to announce its results before the market

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, wh

Scienture signs agreements expanding Rezenopy naloxone for opioid overdose access to 5,000 US instit

Maxim Group analyst Naz Rahman initiates coverage on Scienture Holdings (NASDAQ:SCNX) with a Buy

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical op

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical op

Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch

Scienture Holdings, Inc. (NASDAQ: SCNX - Get Free Report) saw a large increase in short interest in

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan.

New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray.

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annuallyCOMMACK, NY, Dec.